Discord has announced plans to enforce a new "teen-appropriate" experience by default next month, requiring age verification to access restricted content or change content settings. In a blog post ...
Oracle revealed plans to raise up to $50 billion in debt and equity to finance its massive data center commitments The company's 5-year credit default swaps fell 17% as the likelihood of a credit ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...
The Canadian government told Stellantis NV it’s in default on its taxpayer-backed financial aid after it moved auto production to a US plant, Industry Minister Melanie Joly said. Joly first threatened ...
When MS-DOS 5.0 was launched in 1991, one of its major innovations was the MS-DOS Editor, a classic text editor that quickly became popular with users. These days, it’s old news—yet fondly remembered.
Following a ~39% drop in the previous session, Replimune (NASDAQ:REPL) shares continued to trade lower on Friday as J.P. Morgan downgraded the stock to Underweight from Neutral, citing further ...
On July 22, 2025, Replimune publicly announced that the U.S. Food and Drug Administration (FDA) had issued a "Complete Response Letter" (CRL) for its Biologics License Application (BLA) for RP1. This ...
Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Cory Benfield discusses the evolution of ...
Warnings on defaults are starting to pile up in the $1.7 trillion private credit market, prompting at least some analysts to raise concern about underappreciated risks in one of Wall Street’s favorite ...
Maybe you lost your job or faced an unexpected emergency expense. Whatever the reason, you’ve fallen behind on your mortgage — and now there’s a notice of default on your door. But what is a notice of ...
On Monday, Replimune Group Inc. (NASDAQ:REPL) is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage. Shares fell sharply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results